Dr. Behnoosh Afghani, Pediatric Hospitalist - Pediatrics

Dr. Behnoosh Afghani, Pediatric Hospitalist - Pediatrics

  • Behnoosh Afghani MD
  • Office: 714-509-8826
  • Specialty: Hospitalist – Pediatrics
  • Board Certified: Pediatrics, Pediatric Infectious Disease

Dr. Behnoosh Afghani is board-certified in pediatrics and pediatric infectious diseases. Before joining CHOC, Dr. Afghani practiced mainly at UC Irvine Medical Center and Miller Children’s Hospital of Long Beach. She attended medical school at the University of Southern California and the University of California, Los Angeles, for her undergraduate education. She performed her pediatric residency at the University of California, Irvine, and conducted her fellowship training in pediatric infectious diseases at UC Irvine and Miller’s Children Hospital of Long Beach. Dr. Afghani has been voted as one of “Orange County’s Top Doctors” and has been recognized as a “Physician of Excellence” by the Orange County Medical Association.

Behnoosh Afghani MD is on staff at CHOC Hospital in Orange .

Locations

  • CHOC Hospital
    1201 W. La Veta Avenue
    Orange, CA 92868
  • UC Irvine Medical Center
    101 The City Dr. ZOT 4482
    Orange, CA 92868

Education

  • Fellowship
    The University of California, Irvine Miller Children’s Hospital of Long Beach, Long Beach, CA
  • Medical School
    The University of Southern California, Los Angeles, CA
  • Residency
    The University of California, Irvine, CA

Academic Appointments

Clinical Professor, Pediatrics
The University of California, Irvine School of Medicine

Administrative Appointments

  • Director
    Pediatric Hospitalist and Pediatric Infectious Diseases, CHOC Hospital, Orange, CA

Honors and Awards

  • Physician of Excellence
    OCMA
  • Outstanding Teaching Award
    UC Irvine School of Medicine

Professional Organizations

  • American Academy of Pediatrics
  • American Society of Microbiology
  • Infectious Disease Society America
  • International Union Against Tuberculosis
  • Pediatric Infectious Disease Society
  • Western Society of Pediatric Research

Publications

1. He K, Afghani B et al. An Intervention to Reduce Unnecessary Chest Radiographs (CXR) In Respiratory Syncytial Virus (Rsv) Bronchiolitis. J Invest Med 2019; V67, 64. 2. Tang K, Afghani B et al. Leading Risk Factors For Decolonization Failure Of Methicillin Resistant Staphyloccus Aureus (Mrsa): A Comprehensive Literature. J Invest Med 2019; V67: 83. 3. Ly S, Afghani B et al. Association Of Obstructive Sleep Apnea (Osa) And Depression In The Pediatric Population. J Invest Med 2019; V67:67. 4. Hong J, Afghani B et al. Comparison Of 2-Day Dexamethasone Versus 5-Day Prednisone For Treatment Of Pediatric Patients With Acute Asthma Exacerbation. J Invest Med 2019; V67: 67. 5. Solomon V, Afghani B et al. Evaluating The Need For Hospitalization After Uncomplicated Enema Reduction Of Intussusception In The Pediatric Population: A Literature Review. J Invest Med 2019; V67:136. 6. Monshizadeh A, Afghani B et al. Are There Benefits To Animal Assisted Therapy In Pediatric Cancer Patients? J Invest Med 2019; V67: 144. 7. Shin C, Afghani B et alUtility Of Probiotics In Management Of Colic In Infants: A Comprehensive Literature Review. J Invest Med 2019; V67: 151. 8. Dayag H, Afghani B et al. Educational Impact Of Restricting Resident Work Hours: A Comprehensive Literature Review. J Invest Med 2019; V67: 164. 9. Bui A, Afghani B et al. Risk Factors Associated With Recurrent Kawasaki Disease. J Invest Med 2019; V67: 202. 10. Nikroo K, Afghani B, et al. Internet Gaming Disorder (Igd): Associations With Changes In Gray Matter And Behaviors. J Invest Med 2019; V67: 216. 11. Kim J, Afghani B, et al. Surgical Treatment Of Seizures Refractory To Anti-Seizure Medication In The Pediatric Population: A Closer Look At the Literature. J Invest Med 2019; V67:218 12. Cater M, Afghani B et al. Does Rapid Weight Gain In Infancy Predispose To Being Overweight Later In Life? J Invest Med 2019; V67: 227. 13. Lawicki J, Afghani B et al. Combinatorial Immunotherapy With Adjunctive Omalizumab. J Invest Med 2019; V67